Getein Biotech's low P/E ratio is due to declining earnings....
Getein Biotech's low P/E ratio is due to declining earnings. Unless conditions improve, the low P/E ratio and falling share price may persist. The market's expected 41% growth next year puts the company's recent earnings decline into perspective.
![](https://pubimg-10000538.picsh.myqcloud.com/202205090000026380caa80b1ec.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment